Welcome to the homepage of EuCAI
Mission
Provide state of the art cell based screening platforms that advance basic research and drug discovery towards improved prediction of clinical efficacy and safety. In particular, the interest group offers expertise in the development, characterization and application of advanced cell biological models such as 3D culture, co-cultures, primary cells and stem cells for screening purposes. By combining innovations in biological model development with new enabling technologies, EuCAI aims at providing cell based screening services and high content analysis solutions that offer enhanced scientific rigour, mechanistic understanding and clinical relevance to academic translational centres, SMEs and the pharmaceutical industry.
News - EUCAI position paper published
International scientists call for a rethink on industrial and academic drug discovery
A group of prominent scientists shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures. Parallel competitive research and development funding restricted to traditional drug discovery operating models is suggested as one major contributing factor to the exponential increase in the cost of new medicines. The article proposes that early drug discovery efforts would benefit from improved global co-ordination to remove parallel and redundant developments of reusable technologies. >> read more >>
Provide state of the art cell based screening platforms that advance basic research and drug discovery towards improved prediction of clinical efficacy and safety. In particular, the interest group offers expertise in the development, characterization and application of advanced cell biological models such as 3D culture, co-cultures, primary cells and stem cells for screening purposes. By combining innovations in biological model development with new enabling technologies, EuCAI aims at providing cell based screening services and high content analysis solutions that offer enhanced scientific rigour, mechanistic understanding and clinical relevance to academic translational centres, SMEs and the pharmaceutical industry.
News - EUCAI position paper published
International scientists call for a rethink on industrial and academic drug discovery
A group of prominent scientists shared their opinion in Nature Reviews Drug Discovery about ineffective academic and industrial drug discovery investments and funding structures. Parallel competitive research and development funding restricted to traditional drug discovery operating models is suggested as one major contributing factor to the exponential increase in the cost of new medicines. The article proposes that early drug discovery efforts would benefit from improved global co-ordination to remove parallel and redundant developments of reusable technologies. >> read more >>
Member Organizations
University of Oxford, University of Edinburgh, (United Kingdom)
MPI-CBG, EMBL-Heidelberg, DZNE, FMP (Germany)
Institut Pasteur, Institut Curie (France)
FIMM (Finland)
EPFL, ETH, (Switzerland)
Trinity College Dublin (Ireland)
CNIC (Spain)
OcellO (Holland)
SciLifeLab (Sweden)
HAS BRC (Hungary)
University of Oxford, University of Edinburgh, (United Kingdom)
MPI-CBG, EMBL-Heidelberg, DZNE, FMP (Germany)
Institut Pasteur, Institut Curie (France)
FIMM (Finland)
EPFL, ETH, (Switzerland)
Trinity College Dublin (Ireland)
CNIC (Spain)
OcellO (Holland)
SciLifeLab (Sweden)
HAS BRC (Hungary)